

Mediland Pharm Limited (ASX: MPH) (**Mediland** or the **Company**), a market leading retail company focused on servicing the Chinese inbound tourism sector in Australia, is pleased to report its financial results for the half year ended 31 December 2018 (the **Half-Year**) (the **Financial Report**) and its Appendix 4D. On the 22 February 2019, the Group was admitted to the Official List of the ASX Limited, completing an initial Public Offering (IPO) of 64,763,610 new shares at an issue price of \$0.20, raising \$12,952,722 before transaction costs.

## 1. Company details

Reporting period:	For the half-year ended 31 December 2018
Previous period:	For the half-year ended 31 December 2017

## 2. Results for announcement to the market

				Reporting period
Revenues from ordinary activities	Down	24%	to	\$13,358,134
Profit from ordinary activities after tax attributable to the owners of Mediland Pharm Limited	Down	76%	to	\$378,411
Net profit for the period attributable to the owners of Mediland Pharm Limited	Down	76%	to	\$378,411

### Dividends

A fully franked dividend of \$3,552,233 for the year ended 30 June 2018 was declared and paid on 16 October 2018 to PMG, the owner of the Australian businesses prior to the restructuring of the Group.

### Comments

The profit for the Group after providing for income tax amounted to \$378,411 (31 December 2017: \$1,551,073), primarily due to the one-off ASX listing expense of \$552,695 incurred in this period

Further information on the results is detailed in the 'Review of operations' section of the Directors' report which is part of the Interim Report.

## 3. Net tangible assets

	Reporting period	Previous period
Net tangible assets per ordinary security (cents per share)	0.8	1.7

## 4. Control gained over entities

Not applicable.

## 5. Loss of control over entities

Not applicable.

## 6. Dividend reinvestment plans

Not applicable.

## 7. Details of associates and joint venture entities

Not applicable.

**8. Foreign entities**


Not applicable.

**9. Audit qualification or review**

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

**10. Attachments**

The Interim Report of Mediland Pharm Limited for the half-year ended 31 December 2018 is attached.



**Peter French**  
**Chairman**



**Yeshween Mudaliar**  
**Managing Director**  
Sydney

Date: 27 February 2019